一线免疫疗法下接受局部烧蚀疗法治疗寡进展转移性 NSCLC 患者的疗效分析

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical lung cancer Pub Date : 2024-08-08 DOI:10.1016/j.cllc.2024.07.009

C. Huet , C. Basse , M. Knetki-Wroblewska , P. Chilczuk , PE. Bonte , S. Cyrille , E. Gobbini , P. Du Rusquec , M. Olszyna-Serementa , C. Daniel , F. Lucibello , L. Lahmi , M. Krzakowski , N. Girard

{"title":"一线免疫疗法下接受局部烧蚀疗法治疗寡进展转移性 NSCLC 患者的疗效分析","authors":"C. Huet , C. Basse , M. Knetki-Wroblewska , P. Chilczuk , PE. Bonte , S. Cyrille , E. Gobbini , P. Du Rusquec , M. Olszyna-Serementa , C. Daniel , F. Lucibello , L. Lahmi , M. Krzakowski , N. Girard","doi":"10.1016/j.cllc.2024.07.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Context</h3><div>Nonsmall Cell Lung Cancer (NSCLC) treatment relies on first-line immunotherapy as single agent or combined with chemotherapy. Oligoprogression may be observed in this setting.</div></div><div><h3>Material and Method</h3><div>We performed a European multicentric retrospective study on patients treated with first-line immunotherapy, who presented with oligoprogressive disease, treated with a local ablative treatment.</div></div><div><h3>Results</h3><div>A total of 61 patients were retrospectively included between 2018 and 2022. Twenty-four patients (39%) received immunotherapy as single agent, and 37 (61%) chemo-immunotherapy. First oligoprogression occurred more frequently in pre-existing metastatic sites (47% of patients). Median PFS1 (defined as time to first oligoprogression) was 11.5 months [IC95%: 10.0-12.3]. We observed that 37 patients (61%) progressed after first oligoprogression, and 20 (54%) from them presented second oligoprogression. Median OS for the whole cohort was 72.0 months [IC95%: 19.3-124.8], with positive correlation between OS and PFS1 (R=0.65, <em>P</em> < .0001). After loco-ablative treatment with radiotherapy, disease control rate was 89% with ablative radiotherapy: 88% with conventional radiotherapy, and 89% with stereotactic radiotherapy.</div></div><div><h3>Conclusion</h3><div>Patients with oligoprogression under/after immunotherapy have better prognosis with a high risk of subsequent oligoprogression.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 8","pages":"Pages e402-e410.e3"},"PeriodicalIF":3.3000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy\",\"authors\":\"C. Huet , C. Basse , M. Knetki-Wroblewska , P. Chilczuk , PE. Bonte , S. Cyrille , E. Gobbini , P. Du Rusquec , M. Olszyna-Serementa , C. Daniel , F. Lucibello , L. Lahmi , M. Krzakowski , N. Girard\",\"doi\":\"10.1016/j.cllc.2024.07.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Context</h3><div>Nonsmall Cell Lung Cancer (NSCLC) treatment relies on first-line immunotherapy as single agent or combined with chemotherapy. Oligoprogression may be observed in this setting.</div></div><div><h3>Material and Method</h3><div>We performed a European multicentric retrospective study on patients treated with first-line immunotherapy, who presented with oligoprogressive disease, treated with a local ablative treatment.</div></div><div><h3>Results</h3><div>A total of 61 patients were retrospectively included between 2018 and 2022. Twenty-four patients (39%) received immunotherapy as single agent, and 37 (61%) chemo-immunotherapy. First oligoprogression occurred more frequently in pre-existing metastatic sites (47% of patients). Median PFS1 (defined as time to first oligoprogression) was 11.5 months [IC95%: 10.0-12.3]. We observed that 37 patients (61%) progressed after first oligoprogression, and 20 (54%) from them presented second oligoprogression. Median OS for the whole cohort was 72.0 months [IC95%: 19.3-124.8], with positive correlation between OS and PFS1 (R=0.65, <em>P</em> < .0001). After loco-ablative treatment with radiotherapy, disease control rate was 89% with ablative radiotherapy: 88% with conventional radiotherapy, and 89% with stereotactic radiotherapy.</div></div><div><h3>Conclusion</h3><div>Patients with oligoprogression under/after immunotherapy have better prognosis with a high risk of subsequent oligoprogression.</div></div>\",\"PeriodicalId\":10490,\"journal\":{\"name\":\"Clinical lung cancer\",\"volume\":\"25 8\",\"pages\":\"Pages e402-e410.e3\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical lung cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1525730424001475\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424001475","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：非小细胞肺癌（NSCLC）的治疗依赖于一线免疫疗法作为单药或与化疗联合使用。材料与方法：我们对接受一线免疫治疗的患者进行了欧洲多中心回顾性研究：我们对接受一线免疫疗法治疗的患者进行了一项欧洲多中心回顾性研究，这些患者在接受局部消融治疗后出现了少进展性疾病：在2018年至2022年期间，共回顾性纳入了61名患者。24名患者（39%）接受了单药免疫治疗，37名患者（61%）接受了化疗免疫治疗。首次寡核苷酸进展多发生在已存在的转移部位（47%的患者）。中位生存期1（定义为至首次寡进展的时间）为11.5个月[IC95%：10.0-12.3]。我们观察到，37 例患者（61%）在第一次寡核苷酸进展后病情恶化，其中 20 例（54%）出现第二次寡核苷酸进展。全组患者的中位生存期为 72.0 个月 [IC95%：19.3-124.8]，生存期与 PFS1 呈正相关（R=0.65，P < .0001）。放疗局部消融治疗后，消融放疗的疾病控制率为89%：常规放疗为88%，立体定向放疗为89%：结论：接受免疫治疗或治疗后出现寡进展的患者预后较好，但随后出现寡进展的风险较高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy

Context

Nonsmall Cell Lung Cancer (NSCLC) treatment relies on first-line immunotherapy as single agent or combined with chemotherapy. Oligoprogression may be observed in this setting.

Material and Method

We performed a European multicentric retrospective study on patients treated with first-line immunotherapy, who presented with oligoprogressive disease, treated with a local ablative treatment.

Results

A total of 61 patients were retrospectively included between 2018 and 2022. Twenty-four patients (39%) received immunotherapy as single agent, and 37 (61%) chemo-immunotherapy. First oligoprogression occurred more frequently in pre-existing metastatic sites (47% of patients). Median PFS1 (defined as time to first oligoprogression) was 11.5 months [IC95%: 10.0-12.3]. We observed that 37 patients (61%) progressed after first oligoprogression, and 20 (54%) from them presented second oligoprogression. Median OS for the whole cohort was 72.0 months [IC95%: 19.3-124.8], with positive correlation between OS and PFS1 (R=0.65, P < .0001). After loco-ablative treatment with radiotherapy, disease control rate was 89% with ablative radiotherapy: 88% with conventional radiotherapy, and 89% with stereotactic radiotherapy.

Conclusion

Patients with oligoprogression under/after immunotherapy have better prognosis with a high risk of subsequent oligoprogression.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.